Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 4/20 | 0.42 |
| ▸ | TACR1 | P25103 | 8/20 | 0.41 |
| ▸ | SCN4A | P35499 | 5/20 | 0.37 |
| ▸ | AGXT | P21549 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.35 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.35 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5460913 | 1.00 | CYP1A2 (0.47) | CYP1A2CYP2D6CYP2C19IDO1TACR1 | |
| SCHEMBL27482181 | 0.84 | CYP1A2 (0.47) | CYP1A2CYP2D6CYP2C19IDO1TACR1 | |
| SCHEMBL5450360 | 0.84 | CYP1A2 (0.47) | CYP1A2CYP2D6CYP2C19IDO1TACR1 | |
| SCHEMBL8667494 | 0.82 | ESR1 (0.43) | CYP1A2CYP2D6CYP2C19TACR1SCN4A | |
| SCHEMBL8470594 | 0.82 | ESR1 (0.43) | CYP1A2CYP2D6CYP2C19TACR1SCN4A | |
| SCHEMBL4533995 | 0.81 | IDO1 (0.47) | CYP1A2CYP2D6CYP2C19IDO1AGXT | |
| SCHEMBL5458263 | 0.81 | CYP1A2 (0.44) | CYP1A2CYP2D6CYP2C19IDO1TACR1 | |
| SCHEMBL5455498 | 0.81 | CYP1A2 (0.44) | CYP1A2CYP2D6CYP2C19IDO1TACR1 | |
| Hydrochloric Acid SCHEMBL17220823 | 0.80 | ALOX15 (0.44) | CYP1A2CYP2D6CYP2C19IDO1TACR1 | |
| SCHEMBL13877377 | 0.79 | IDO1 (0.50) | CYP1A2CYP2D6CYP2C19IDO1AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420679-B2 | Aminothiazole derivatives and their use as CRF receptor ligands | SANOFI (FR) | 2013-04-16 | — | — | US | disclosed |
| US-20070281919-A1 | Aminothiazole Derivatives And Their Use As CRF Receptor Ligands | SANOFI-AVENTIS (FR) | 2007-12-06 | — | — | US | disclosed |
| EP-1200419-B1 | AMINOTHIAZOLE DERIVATIVES AND THEIR USE AS CRF RECEPTOR LIGANDS | SANOFI SYNTHELABO (FR) | 2004-04-14 | — | — | EP | disclosed |
| US-6586456-B1 | Corticotropin releasing factor (CRF) antagonists such as (4-(2-chloro-4-methoxy-5-methylphenyl)-5-methylthiazol-2-yl)(( (1-(3-fluoro-4-methylphenyl)-2-methoxyethyl))prop-2-ynylamine, prepared by alkylation with propagyl bromide | SANOFI-SYNTHELABO (FR) | 2003-07-01 | — | — | US | disclosed |
| EP-1200419-A1 | AMINOTHIAZOLE DERIVATIVES AND THEIR USE AS CRF RECEPTOR LIGANDS | SANOFI-SYNTHELABO (FR) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001005776-A1 | AMINOTHIAZOLE DERIVATIVES AND THEIR USE AS CRF RECEPTOR LIGANDS | SANOFI-SYNTHELABO (FR) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281919-A1 | Aminothiazole Derivatives And Their Use As CRF Receptor Ligands | CRH, CRHR1, CRHR2 | CYP1A2 3410/4885CYP2D6 3094/4885CYP2C19 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.